QUOTE AND NEWS
Benzinga  Jun 12  Comment 
LeapFrog Enterprises, Inc. (NYSE: LF) dipped 18.60 percent to $1.68. LeapFrog reported a Q4 loss of $0.56 per share on revenue of $33.9 million. Optical Cable Corporation (NASDAQ: OCC) shares dropped 11.39 percent to $3.58. Optical Cable...
Benzinga  Jun 3  Comment 
Ferrellgas Partners, L.P. (NYSE: FGP) shares declined 3.70 percent to $22.64 in pre-market trading after the company priced an offering of 6,325,000 common units at $23.00 per unit. NuVasive, Inc. (NASDAQ: NUVA) shares fell 1.56 percent to...
Benzinga  May 21  Comment 
Joel Elconin is the co-host of Benzinga's #PreMarket Prep, a daily trading idea radio show. AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) shares were trading higher by $1.36 (80 percent) at $2.96 in Thursday's session. The catalyst for the issue...
Benzinga  May 20  Comment 
AVEO Oncology (NASDAQ: AVEO) announced today that final results from the TIVO-1 extension study, known as Study 902, in which patients with advanced renal cell carcinoma (RCC) received tivozanib as second-line treatment subsequent to disease...
Benzinga  Mar 9  Comment 
Analysts at RBC Capital upgraded AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) from Underperform to Sector Perform. The price target for AVEO Pharmaceuticals has been raised from $2.00 to $3.00. AVEO Pharmaceuticals shares have dropped 22.28%...
Benzinga  Mar 9  Comment 
Benzinga  Mar 6  Comment 
Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) shares soared Friday after the company said its tivozanib cancer drug obtained superior results compared with Roche Holding Ltd.'s (OTC: RHHBY) Avastin in a subgroup of patients in a Phase II...
Benzinga  Mar 6  Comment 
Calithera Biosciences Inc (NASDAQ: CALA) shares jumped 28.90% to $17.16 after the company obtained rights to develop and commercialize a portfolio of preclinical compounds aimed at treating cancer from TransTech Pharma. AVEO Pharmaceuticals,...
Benzinga  Nov 11  Comment 
AVEO Oncology (NASDAQ: AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's...
DailyFinance  Sep 29  Comment 
AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the...
DailyFinance  Sep 26  Comment 
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in...




 

AVEO Pharmaceuticals (AVEO) (NASDAQ:AVEO) is a pharmaceutical drug company that specializes on cancer treatments. It has a cancer treatment product, tivozanib, in Phase 3 of the FDA approval process. It also is in collaboration with Merck for a cancer treatment product AV-299, which helps determine cancer biology in patients. This product is in Phase 2. [1]

Along with other pharmaceutical companies, government regulation and the FDA approval process decides whether a pharmaceutical company's drug can enter the commercial market. AVEO is dependent on its cancer treatment product, tivozanib, to pass Phase 3 and enter the commercial market, otherwise it decreases future earnings as the company either scraps the product or reinvest and restart the process. Since it already passed Phase 2, it is expected to have a positive outcome for Phase 3. [1]

The company's initial public offering of stock traded on the NASDAQ exchange on 11 March 2010. The proposed offer price range was $13-$15 and traded below the low end at $9. The company offered 9 million shares and raised $81 million. [1]

At the year end 31 December 2009, the company had $20.72 million in total revenue, up 5.4% from $19.66 million in total revenue in 2008. The company reported a net loss of $44.2 million, down from a net loss of $32.47 million. [1]

References

  1. 1.0 1.1 1.2 1.3 AVEO Pharmaceuticals S-1/A
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki